Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…

BySenior EditorMarch 31, 2022

TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…

ByPrince GiriFebruary 10, 2022

VIEWPOINTS

PharmaShots Interview: AstraZeneca’s Alexander Bedenkov Shares Insight on First Virtual Events with Slush to Improve Patients Outcomes

In an interview with PharmaShots, Alexander Bedenkov, Vice President, Medical International Region & Global Health Innovation Hubs (A.Catalyst) Network Head at AstraZeneca shares his views on the First Virtual Events in collaboration with Slush to accelerate better health outcomes through innovation Shots: The companies collaborated to launch virtual events and enhance collaboration in the healthcare sector. The event was run through AstraZeneca’s A.Catalyst Network,…

BySenior EditorDecember 13, 2021

VIEWPOINTS

PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153

In an interview with PharmaShots, Dr. Barbara Klencke, MD, Chief Medical Officer at Sierra Oncology share her views on the license agreement for AZD5153 with AstraZeneca to treat myelofibrosis Shots: AstraZeneca signs an exclusive license agreement with Sierra for AZD5153 to expand myelofibrosis pipeline. The agreement will provide a novel compound into Sierra's pipeline to supply therapies for rare cancers Sierra plans…

BySenior EditorOctober 11, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

TOP 20

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy Our team at PharmaShots has compiled a list of top 20 oncology companies based on…

ByPrince GiriSeptember 9, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021 Additionally, last year in 2020, the US FDA…

BySenior EditorJuly 7, 2021

TOP 20

Top 20 BioPharma Companies based on 2020 Total Revenue

Despite having the global Covid-19 pandemic- the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally All of the Biopharma companies on our list are on the front line to combat this global crisis. The top…

ByPrince GiriApril 8, 2021

VIEWPOINTS

PharmaShots Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

In an interview with PharmaShots, John Valliant, CEO at Fusion Pharma shared his views on the company's agreement with AstraZeneca, signed in Nov 2020. He also shared in-depth information about the company's TATs platform & Fast-Clear linker technology and provide a glance at Fusion's portfolio. Shots: Fusion to receive $5M up front and $40M as milestones & other payments. The…

BySenior EditorMarch 24, 2021

Top 20 BioPharma Companies based on 2021 Total Revenue

PharmaShots’ Key Highlights of First Quarter 2022

Top 20 Life Sciences Deals of 2021 by Total Deal Value

PharmaShots Interview: AstraZeneca’s Alexander Bedenkov Shares Insight on First Virtual Events with Slush to Improve Patients Outcomes

PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153

PharmaShots’ Key Highlights of Third Quarter 2021

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

PharmaShots’ Key Highlights of Second Quarter 2021

Top 20 BioPharma Companies based on 2020 Total Revenue

PharmaShots Interview: Fusion Pharma’s John Valliant Shares Insight on its Collaboration with AstraZeneca

Contact US

OUR INFORMATION

FOLLOW US